CALZF 1.19 PolyNovo Limited
| Range: | 0.513-1.8 | Vol Avg: | 1782 | Last Div: | 0 | Changes: | 0.05 |
| Beta: | 1.67 | Cap: | 1.24B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Fri Jan 08 2021 | Empoloyees: | 254 | ||
| CUSIP: | CIK: | ISIN: | AU000000PNV0 | Country: | AU | ||
| CEO: | Mr. Swami Raote BPHARM, M.B.A. | Website: | https://polynovo.com | ||||
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow